Invivyd Presents Preclinical Data Showing Measles Antibody Candidate VMS063 Demonstrates Potent Antiviral Activity Against Contemporary Measles Fusion Protein Variants

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus